Concepedia

Magali Vercauteren

MV

7

Publications

343

Citations

7

H-Index

2006

Active since

Affiliations

Actelion (Switzerland)(Current)

Inserm

Université de Rouen Normandie

Magali Vercauteren is an author at Actelion (Switzerland) specializing in medicine, cardiovascular pharmacology, and cardiovascular disease.

Top concepts

Publications per year

2006–2018

7

Publications

7

Endothelin ETA Receptor Blockade, by Activating ETB Receptors, Increases Vascular Permeability and Induces Exaggerated Fluid Retention

Magali Vercauteren, F. Trensz, Anne Pasquali et al. · Journal of Pharmacology and Experimental Therapeutics · 2017 · 80 citations

Improvement of Peripheral Endothelial Dysfunction by Protein Tyrosine Phosphatase Inhibitors in Heart Failure

Magali Vercauteren, Elise Rémy, Corinne Devaux et al. · Circulation · 2006 · 71 citations

Reduction of heart failure by pharmacological inhibition or gene deletion of protein tyrosine phosphatase 1B

Élodie Gomez, Magali Vercauteren, Baptiste Kurtz et al. · Journal of Molecular and Cellular Cardiology · 2012 · 55 citations

, , +11

Heart Rate Reduction Induced by the If Current Inhibitor Ivabradine Improves Diastolic Function and Attenuates Cardiac Tissue Hypoxia

Yuehua Fang, Manuelle Debunne, Magali Vercauteren et al. · Journal of Cardiovascular Pharmacology · 2011 · 49 citations

Serotonin biosynthesis as a predictive marker of serotonin pharmacodynamics and disease-induced dysregulation

Richard W.D. Welford, Magali Vercauteren, Annette Trébaul et al. · Scientific Reports · 2016 · 41 citations · Full text

Rows per page

1–5 of 7